Эффективность и безопасность длительной терапии хронического гепатита В нуклеозидными и нуклеотидными аналогами - Журнал Терапевтический архив №2 Вопросы гастроэнтерологии 2019
Эффективность и безопасность длительной терапии хронического гепатита В нуклеозидными и нуклеотидными аналогами
Ибрагимов Э.К., Абдурахманов Д.Т., Розина Т.П. и др. Эффективность и безопасность длительной терапии хронического гепатита В нуклеозидными и нуклеотидными аналогами. Терапевтический архив. 2019; 91 (2): 8–47. DOI: 10.26442/ 00403660.2019.02.000073
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Аналоги нуклеоз(т)идов (АН) наиболее часто применяются в лечении хронического гепатита В. Однако необходимая длительность, эффективность и безопасность лечения АН остаются предметом дискуссии.
Цель исследования. Изучение эффективности и безопасности длительной терапии АН больных хроническим гепатитом В (ХГВ).
Материалы и методы. В исследование включены больные ХГВ (n=101), которые за период с 2008 по 2017 г. получали лечение тенофовиром, энтекавиром и телбивудином в течение как минимум 3 лет (максимально – в течение 9 лет).
Результаты и обсуждение. При длительном лечении энтекавиром и тенофовиром увеличивается кумулятивная частота авиремии (более 95% после 3 лет терапии), сероконковерсии HBeAg (93 и 67%, соответственно) и нормализации активности аланинаминотрансферазы (в 95% случаев). Частота развития резистентности при длительном лечении тенофовиром, энтекавиром и телбивудином составила 0; 3,1 и 43,5%, соответственно. При длительном лечении АН наблюдается регресс фиброза печени (с 8,92 до 7,18 кПа; р<0,0001) и уменьшение доли больных с выраженным фиброзом (с 48,1 до 13,8%; р<0,0001).
Заключение. Энтекавир и тенофовир могут рассматриваться как наиболее эффективные и безопасные препараты при длительном лечении ХГВ.
Ключевые слова: хронический гепатит В, аналоги нуклеоз(т)идов, вирусологический ответ, сероконверсия HBeAg, клиренс HBsAg, нормализация аланинаминотрансферазы, безопасность.
Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B.
Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine.
Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95%) and HBeAg seroconversion (93% and 67%, respectively). Cumulative rate of virologic resistance was 0; 3.1% and 43.5% for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, р<0.0001) and reduction in the number of patients with advanced fibrosis (from 48.1% to 13.8%, р<0.0001). Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases.
Conclusion. Entecavir and tenofovir might be recommended for the treatment of chronic hepatitis B because of having potent antiviral effect, high genetic barriers against resistance and good safety.
Key words: chronic hepatitis B, nucleos(t)ide analogues, virologic response, HBeAg seroconversion, HBsAg clearance, ALT normalization, safety.
Цель исследования. Изучение эффективности и безопасности длительной терапии АН больных хроническим гепатитом В (ХГВ).
Материалы и методы. В исследование включены больные ХГВ (n=101), которые за период с 2008 по 2017 г. получали лечение тенофовиром, энтекавиром и телбивудином в течение как минимум 3 лет (максимально – в течение 9 лет).
Результаты и обсуждение. При длительном лечении энтекавиром и тенофовиром увеличивается кумулятивная частота авиремии (более 95% после 3 лет терапии), сероконковерсии HBeAg (93 и 67%, соответственно) и нормализации активности аланинаминотрансферазы (в 95% случаев). Частота развития резистентности при длительном лечении тенофовиром, энтекавиром и телбивудином составила 0; 3,1 и 43,5%, соответственно. При длительном лечении АН наблюдается регресс фиброза печени (с 8,92 до 7,18 кПа; р<0,0001) и уменьшение доли больных с выраженным фиброзом (с 48,1 до 13,8%; р<0,0001).
Заключение. Энтекавир и тенофовир могут рассматриваться как наиболее эффективные и безопасные препараты при длительном лечении ХГВ.
Ключевые слова: хронический гепатит В, аналоги нуклеоз(т)идов, вирусологический ответ, сероконверсия HBeAg, клиренс HBsAg, нормализация аланинаминотрансферазы, безопасность.
________________________________________________
Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B.
Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine.
Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95%) and HBeAg seroconversion (93% and 67%, respectively). Cumulative rate of virologic resistance was 0; 3.1% and 43.5% for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, р<0.0001) and reduction in the number of patients with advanced fibrosis (from 48.1% to 13.8%, р<0.0001). Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases.
Conclusion. Entecavir and tenofovir might be recommended for the treatment of chronic hepatitis B because of having potent antiviral effect, high genetic barriers against resistance and good safety.
Key words: chronic hepatitis B, nucleos(t)ide analogues, virologic response, HBeAg seroconversion, HBsAg clearance, ALT normalization, safety.
Список литературы
1. World Health Organization. Global hepatitis report 2017; April 21, 2017; Geneva. Available from: at: http://apps.who.int/iris/bitstream/ handle/10665/255016/9789241565455-eng.pdf?sequence=1&isAllowed=y (Accessed September 15, 2018).
2. World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: March 2015; March 12, 2015; Geneva. Available at: http://apps.who.int/iris/bitstream/handle/10665/154590/?sequence=1 (Accessed September 15, 2018).
3. Абдурахманов Д.Т., Отрашевская A.В. Энтекавир в лечении хронического гепатита В: многоцентровые рандомизированные исследования и реальная клиническая практика. Терапевтический архив. 2014;86(11):100-4 [Abdurakhmanov DT, Otrashevskaya AV. Entekavir for treatment chronic hepatitis B. / Multicenter randomized stydies and real practice. Therapeutic Archive. 2014;86(11):100-4 (In Russ.)].
4. Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты: клиника, диагностика, лечение. М.: ГЭОТАР-Медиа, 2014 [Yushchuk ND, Klimova EA, Znoiko OO, Karetkina GN, Maksimov SL, Mayev IV. Virusniye hepatity: clinica, diagnostica, lecheniye [Viral hepatitis: clinical presentation, diagnosis, treatment]. Мoscow: GEOTAR-Media, 2014 (In Russ.)].
5. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Шестакова И.В., Маев И.В., Павлов Ч.С., Федосьина Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Диагностика и лечение гепатита В у взрослых: консенсус экспертов. Инфекционные болезни: Новости. Мнения. Обучение. 2013;4(5):75-102 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YV, Shestakova IV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YG, Kozevnikova GM, Zhdanov KV, Rakhmanov AG, Closets VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Hepatitis B: diagnosis and treatment in adults. Expert consensus. Infektsionnye Bolezni: Novosti. Mneniya. Obuchenie. 2013;4(5):75-102 (In Russ.)].
6. Абдурахманов Д.Т., Моисеев С.В. Выбор аналога нуклеоз(т)идов для лечения хронического гепатита В. Клиническая фармакология и терапия. 2014;23(1):10-6 [Abdurakhmanov DT, Moiseev SV. The choice of nucleos(t)ide analogue for the treatment of chronic hepatitis B. Klinicheskaya Farmakologiya I Terapiya. 2014;23(1):10-6 (In Russ.)].
7. European Association for The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010
8. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021
9. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Маев И.В., Павлов Ч.С., Федосьина Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Лапина Т.Л., Трухманов А.С., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(3):58-88 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YuV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YaG, Lapina TL, Trukhmanov AS, Kozhevnikova GM, Zhdanov KV, Rakhmanov AG, Chulanov VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;24(3):58-88 (In Russ.)].
10. European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001
11. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242-7. doi: 10.1111/j.1478-3231.2008.01802.x
12. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472
13. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037
14. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-64. doi: 10.1007/s10620-014-3486-7
15. Lampertico P, Soffredini R, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti A, Buti M, Esteban R, Zaltron S, Vavassori A, Castelli F, Viganò M, Rumi MG, Vinci M, Belli LS, Cologni G, Rizzi M, Milanese M, Strazzabosco M, Minola E, Giorgini AM, Zuin M, Salmi A, Colombo S, Fracassetti O, Del Poggio P, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Colombo AE, Bellati G, Angeli E, Gubertini GA, Rizzardini G, Fasano M, Santantonio T, Terreni NM, Spinzi G, Facchetti F, Invernizzi F, Mangia G, Colombo M. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Dig Liv Dis. 2014;46(suppl 1):e14. doi: 10.1016/j.dld.2014.01.033
16. Мамонова Н.А., Сухарева Г.В., Чуланов В.П., Карандашова И.В., Лебедева Е.Б., Пименов Н.Н. Эффективность энтекавира у ламивудин-рефрактерных больных хроническим гепатитом В при раннем переключении с ламивудина на энтекавир: предварительный анализ результатов трехлетнего исследования. Инфекционные болезни. 2014;12(1):81-6 [Mamonova NA, Sukhareva GV, Chulanov VP, Karandashova IV, Lebedeva EB, Pimenov NN. Efficacy of entecavir in lamivudine-refractory patients with chronic hepatitis in early lamivudine-to-entecavir switching: preliminary analysis of the results of a three-year study. Infektsionnye Bolezni. 2014;12(1):81-6 (In Russ)].
17. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, Tanwandee T. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res. 2017;47(3):E161-E168. doi: 10.1111/hepr.12743
18. Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003
19. Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17(1):39. doi: 10.1186/s12876-017-0596-7
20. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37-46. doi: 10.1111/jvh.12025
21. Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat. 2017;24(suppl 1):29-35. doi: 10.1111/jvh.12794
22. Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20(2):O90-O100. doi: 10.1111/1469-0691.12220
23. Ефремова О.С., Кожевникова Г.М., Вознесенский С.Л., Аликеева Г.К. Эффективность современных нуклеозидных аналогов в лечении больных HbeAg-негативным хроническим гепатитом В. Инфекционные болезни. 2013;11(4):5-11 [Efremova OS, Kozhevnikova GM, Voznesenskiy SL, Alikeeva GK. Effectiveness of modern nucleoside analogues in treatment of patients with HBeAg-negative chronic hepatitis В. Infektsionnye Bolezni. 2013;11(4):5-11 (In Russ.)].
24. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014;28:153-9. doi: 10.1016/j.ijid.2014.09.004
25. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22(5):504-10. doi: 10.1111/jvh.12358
26. Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol. 2018;42(1):40-7. doi: 10.1016/j.clinre.2017.06.008
27. Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2009;5:789-98. doi: 10.2147/tcrm.s5318
28. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283-92. doi: 10.1002/hep.26885
29. Wang J, Du LY, Zhu X, Chen EQ, Tang H. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Ind J Med Microbiol. 2015;33(5):20-5. doi: 10.4103/0255-0857.148827
30. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(1):95. doi: 10.1016/j.cmi.2015.05.035
31. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1
32. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93. doi: 10.1002/hep.23785
33. Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol: WJG. 2015;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598
34. Чуланов В.П. Резистентность к противовирусным препаратам при хроническом гепатите В. Фарматека. 2010;(4):20-6 [Chulanov VP. Resistance to antiviral drugs in chronic hepatitis В. Farmateka. 2010;(4):20-6 (In Russ.)].
35. Абдурахманов Д.Т., Моисеев С.В. Безопасность длительной терапии тенофовиром у больных хроническим гепатитом B. Клиническая фармакология и терапия. 2014;23(2):20-5 [Abdurakhmanov DT, Moiseev SV. The safety of long-term tenofovir treatment in patients with chronic hepatitis B. Klinicheskaya Farmakologiya i Terapiya. 2014;23(2):20-5 (In Russ.)].
36. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223-33. doi: 10.1038/ajg.2014.145
37. Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. Yonsei Med J. 2018;59(3):383-8. doi: 10.3349/ymj.2018.59.3.383
38. Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, Chotiyaputta W, Nimanong S. Efficacy and Safety of Entecavir Treatment of Chronic Hepatitis B Patients in Real-world clinical Practice: 968. Hepatology. 2013;58:672A. doi: 10.1002/hep.26856
39. Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gure S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials: 229. Hepatology. 2014;60:313A-314A. doi: 10.1002/hep.27486
2. World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: March 2015; March 12, 2015; Geneva. Available at: http://apps.who.int/iris/bitstream/handle/10665/154590/?sequence=1 (Accessed September 15, 2018).
3. Abdurakhmanov DT, Otrashevskaya AV. Entekavir for treatment chronic hepatitis B. / Multicenter randomized stydies and real practice. Therapeutic Archive. 2014;86(11):100-4 (In Russ.)
4. Yushchuk ND, Klimova EA, Znoiko OO, Karetkina GN, Maksimov SL, Mayev IV. Virusniye hepatity: clinica, diagnostica, lecheniye [Viral hepatitis: clinical presentation, diagnosis, treatment]. Мoscow: GEOTAR-Media, 2014 (In Russ.)
5. Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YV, Shestakova IV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YG, Kozevnikova GM, Zhdanov KV, Rakhmanov AG, Closets VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Hepatitis B: diagnosis and treatment in adults. Expert consensus. Infektsionnye Bolezni: Novosti. Mneniya. Obuchenie. 2013;4(5):75-102 (In Russ.)
6. Abdurakhmanov DT, Moiseev SV. The choice of nucleos(t)ide analogue for the treatment of chronic hepatitis B. Klinicheskaya Farmakologiya I Terapiya. 2014;23(1):10-6 (In Russ.)
7. European Association for The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010
8. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021
9. Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YuV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YaG, Lapina TL, Trukhmanov AS, Kozhevnikova GM, Zhdanov KV, Rakhmanov AG, Chulanov VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;24(3):58-88 (In Russ.)
10. European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001
11. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242-7. doi: 10.1111/j.1478-3231.2008.01802.x
12. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472
13. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037
14. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-64. doi: 10.1007/s10620-014-3486-7
15. Lampertico P, Soffredini R, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti A, Buti M, Esteban R, Zaltron S, Vavassori A, Castelli F, Viganò M, Rumi MG, Vinci M, Belli LS, Cologni G, Rizzi M, Milanese M, Strazzabosco M, Minola E, Giorgini AM, Zuin M, Salmi A, Colombo S, Fracassetti O, Del Poggio P, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Colombo AE, Bellati G, Angeli E, Gubertini GA, Rizzardini G, Fasano M, Santantonio T, Terreni NM, Spinzi G, Facchetti F, Invernizzi F, Mangia G, Colombo M. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Dig Liv Dis. 2014;46(suppl 1):e14. doi: 10.1016/j.dld.2014.01.033
16. Mamonova NA, Sukhareva GV, Chulanov VP, Karandashova IV, Lebedeva EB, Pimenov NN. Efficacy of entecavir in lamivudine-refractory patients with chronic hepatitis in early lamivudine-to-entecavir switching: preliminary analysis of the results of a three-year study. Infektsionnye Bolezni. 2014;12(1):81-6 (In Russ)
17. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, Tanwandee T. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res. 2017;47(3):E161-E168. doi: 10.1111/hepr.12743
18. Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003
19. Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17(1):39. doi: 10.1186/s12876-017-0596-7
20. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37-46. doi: 10.1111/jvh.12025
21. Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat. 2017;24(suppl 1):29-35. doi: 10.1111/jvh.12794
22. Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20(2):O90-O100. doi: 10.1111/1469-0691.12220
23. Efremova OS, Kozhevnikova GM, Voznesenskiy SL, Alikeeva GK. Effectiveness of modern nucleoside analogues in treatment of patients with HBeAg-negative chronic hepatitis В. Infektsionnye Bolezni. 2013;11(4):5-11 (In Russ.)
24. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014;28:153-9. doi: 10.1016/j.ijid.2014.09.004
25. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22(5):504-10. doi: 10.1111/jvh.12358
26. Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol. 2018;42(1):40-7. doi: 10.1016/j.clinre.2017.06.008
27. Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2009;5:789-98. doi: 10.2147/tcrm.s5318
28. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283-92. doi: 10.1002/hep.26885
29. Wang J, Du LY, Zhu X, Chen EQ, Tang H. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Ind J Med Microbiol. 2015;33(5):20-5. doi: 10.4103/0255-0857.148827
30. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(1):95. doi: 10.1016/j.cmi.2015.05.035
31. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1
32. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93. doi: 10.1002/hep.23785
33. Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol: WJG. 2015;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598
34. Chulanov VP. Resistance to antiviral drugs in chronic hepatitis В. Farmateka. 2010;(4):20-6 (In Russ.)
35. Abdurakhmanov DT, Moiseev SV. The safety of long-term tenofovir treatment in patients with chronic hepatitis B. Klinicheskaya Farmakologiya i Terapiya. 2014;23(2):20-5 (In Russ.)
36. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223-33. doi: 10.1038/ajg.2014.145
37. Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. Yonsei Med J. 2018;59(3):383-8. doi: 10.3349/ymj.2018.59.3.383
38. Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, Chotiyaputta W, Nimanong S. Efficacy and Safety of Entecavir Treatment of Chronic Hepatitis B Patients in Real-world clinical Practice: 968. Hepatology. 2013;58:672A. doi: 10.1002/hep.26856
39. Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gure S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials: 229. Hepatology. 2014;60:313A-314A. doi: 10.1002/hep.27486
2. World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: March 2015; March 12, 2015; Geneva. Available at: http://apps.who.int/iris/bitstream/handle/10665/154590/?sequence=1 (Accessed September 15, 2018).
3. Абдурахманов Д.Т., Отрашевская A.В. Энтекавир в лечении хронического гепатита В: многоцентровые рандомизированные исследования и реальная клиническая практика. Терапевтический архив. 2014;86(11):100-4 [Abdurakhmanov DT, Otrashevskaya AV. Entekavir for treatment chronic hepatitis B. / Multicenter randomized stydies and real practice. Therapeutic Archive. 2014;86(11):100-4 (In Russ.)].
4. Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты: клиника, диагностика, лечение. М.: ГЭОТАР-Медиа, 2014 [Yushchuk ND, Klimova EA, Znoiko OO, Karetkina GN, Maksimov SL, Mayev IV. Virusniye hepatity: clinica, diagnostica, lecheniye [Viral hepatitis: clinical presentation, diagnosis, treatment]. Мoscow: GEOTAR-Media, 2014 (In Russ.)].
5. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Шестакова И.В., Маев И.В., Павлов Ч.С., Федосьина Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Диагностика и лечение гепатита В у взрослых: консенсус экспертов. Инфекционные болезни: Новости. Мнения. Обучение. 2013;4(5):75-102 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YV, Shestakova IV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YG, Kozevnikova GM, Zhdanov KV, Rakhmanov AG, Closets VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Hepatitis B: diagnosis and treatment in adults. Expert consensus. Infektsionnye Bolezni: Novosti. Mneniya. Obuchenie. 2013;4(5):75-102 (In Russ.)].
6. Абдурахманов Д.Т., Моисеев С.В. Выбор аналога нуклеоз(т)идов для лечения хронического гепатита В. Клиническая фармакология и терапия. 2014;23(1):10-6 [Abdurakhmanov DT, Moiseev SV. The choice of nucleos(t)ide analogue for the treatment of chronic hepatitis B. Klinicheskaya Farmakologiya I Terapiya. 2014;23(1):10-6 (In Russ.)].
7. European Association for The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010
8. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021
9. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Маев И.В., Павлов Ч.С., Федосьина Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Лапина Т.Л., Трухманов А.С., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(3):58-88 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YuV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YaG, Lapina TL, Trukhmanov AS, Kozhevnikova GM, Zhdanov KV, Rakhmanov AG, Chulanov VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;24(3):58-88 (In Russ.)].
10. European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001
11. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242-7. doi: 10.1111/j.1478-3231.2008.01802.x
12. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472
13. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037
14. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-64. doi: 10.1007/s10620-014-3486-7
15. Lampertico P, Soffredini R, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti A, Buti M, Esteban R, Zaltron S, Vavassori A, Castelli F, Viganò M, Rumi MG, Vinci M, Belli LS, Cologni G, Rizzi M, Milanese M, Strazzabosco M, Minola E, Giorgini AM, Zuin M, Salmi A, Colombo S, Fracassetti O, Del Poggio P, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Colombo AE, Bellati G, Angeli E, Gubertini GA, Rizzardini G, Fasano M, Santantonio T, Terreni NM, Spinzi G, Facchetti F, Invernizzi F, Mangia G, Colombo M. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Dig Liv Dis. 2014;46(suppl 1):e14. doi: 10.1016/j.dld.2014.01.033
16. Мамонова Н.А., Сухарева Г.В., Чуланов В.П., Карандашова И.В., Лебедева Е.Б., Пименов Н.Н. Эффективность энтекавира у ламивудин-рефрактерных больных хроническим гепатитом В при раннем переключении с ламивудина на энтекавир: предварительный анализ результатов трехлетнего исследования. Инфекционные болезни. 2014;12(1):81-6 [Mamonova NA, Sukhareva GV, Chulanov VP, Karandashova IV, Lebedeva EB, Pimenov NN. Efficacy of entecavir in lamivudine-refractory patients with chronic hepatitis in early lamivudine-to-entecavir switching: preliminary analysis of the results of a three-year study. Infektsionnye Bolezni. 2014;12(1):81-6 (In Russ)].
17. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, Tanwandee T. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res. 2017;47(3):E161-E168. doi: 10.1111/hepr.12743
18. Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003
19. Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17(1):39. doi: 10.1186/s12876-017-0596-7
20. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37-46. doi: 10.1111/jvh.12025
21. Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat. 2017;24(suppl 1):29-35. doi: 10.1111/jvh.12794
22. Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20(2):O90-O100. doi: 10.1111/1469-0691.12220
23. Ефремова О.С., Кожевникова Г.М., Вознесенский С.Л., Аликеева Г.К. Эффективность современных нуклеозидных аналогов в лечении больных HbeAg-негативным хроническим гепатитом В. Инфекционные болезни. 2013;11(4):5-11 [Efremova OS, Kozhevnikova GM, Voznesenskiy SL, Alikeeva GK. Effectiveness of modern nucleoside analogues in treatment of patients with HBeAg-negative chronic hepatitis В. Infektsionnye Bolezni. 2013;11(4):5-11 (In Russ.)].
24. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014;28:153-9. doi: 10.1016/j.ijid.2014.09.004
25. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22(5):504-10. doi: 10.1111/jvh.12358
26. Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol. 2018;42(1):40-7. doi: 10.1016/j.clinre.2017.06.008
27. Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2009;5:789-98. doi: 10.2147/tcrm.s5318
28. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283-92. doi: 10.1002/hep.26885
29. Wang J, Du LY, Zhu X, Chen EQ, Tang H. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Ind J Med Microbiol. 2015;33(5):20-5. doi: 10.4103/0255-0857.148827
30. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(1):95. doi: 10.1016/j.cmi.2015.05.035
31. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1
32. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93. doi: 10.1002/hep.23785
33. Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol: WJG. 2015;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598
34. Чуланов В.П. Резистентность к противовирусным препаратам при хроническом гепатите В. Фарматека. 2010;(4):20-6 [Chulanov VP. Resistance to antiviral drugs in chronic hepatitis В. Farmateka. 2010;(4):20-6 (In Russ.)].
35. Абдурахманов Д.Т., Моисеев С.В. Безопасность длительной терапии тенофовиром у больных хроническим гепатитом B. Клиническая фармакология и терапия. 2014;23(2):20-5 [Abdurakhmanov DT, Moiseev SV. The safety of long-term tenofovir treatment in patients with chronic hepatitis B. Klinicheskaya Farmakologiya i Terapiya. 2014;23(2):20-5 (In Russ.)].
36. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223-33. doi: 10.1038/ajg.2014.145
37. Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. Yonsei Med J. 2018;59(3):383-8. doi: 10.3349/ymj.2018.59.3.383
38. Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, Chotiyaputta W, Nimanong S. Efficacy and Safety of Entecavir Treatment of Chronic Hepatitis B Patients in Real-world clinical Practice: 968. Hepatology. 2013;58:672A. doi: 10.1002/hep.26856
39. Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gure S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials: 229. Hepatology. 2014;60:313A-314A. doi: 10.1002/hep.27486
________________________________________________
2. World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: March 2015; March 12, 2015; Geneva. Available at: http://apps.who.int/iris/bitstream/handle/10665/154590/?sequence=1 (Accessed September 15, 2018).
3. Abdurakhmanov DT, Otrashevskaya AV. Entekavir for treatment chronic hepatitis B. / Multicenter randomized stydies and real practice. Therapeutic Archive. 2014;86(11):100-4 (In Russ.)
4. Yushchuk ND, Klimova EA, Znoiko OO, Karetkina GN, Maksimov SL, Mayev IV. Virusniye hepatity: clinica, diagnostica, lecheniye [Viral hepatitis: clinical presentation, diagnosis, treatment]. Мoscow: GEOTAR-Media, 2014 (In Russ.)
5. Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YV, Shestakova IV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YG, Kozevnikova GM, Zhdanov KV, Rakhmanov AG, Closets VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Hepatitis B: diagnosis and treatment in adults. Expert consensus. Infektsionnye Bolezni: Novosti. Mneniya. Obuchenie. 2013;4(5):75-102 (In Russ.)
6. Abdurakhmanov DT, Moiseev SV. The choice of nucleos(t)ide analogue for the treatment of chronic hepatitis B. Klinicheskaya Farmakologiya I Terapiya. 2014;23(1):10-6 (In Russ.)
7. European Association for The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010
8. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021
9. Ivashkin VT, Yushchuk ND, Mayevskaya MV, Znoyko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YuV, Mayev IV, Pavlov ChS, Fedosyina EA, Buyeverov AO, Abdurakhmanov DT, Malyshev NA, Nikitin IG, Moysyuk YaG, Lapina TL, Trukhmanov AS, Kozhevnikova GM, Zhdanov KV, Rakhmanov AG, Chulanov VP, Shakhgildyan IV, Syutkin VE, Bogomolov PO. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;24(3):58-88 (In Russ.)
10. European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001
11. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242-7. doi: 10.1111/j.1478-3231.2008.01802.x
12. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472
13. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037
14. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-64. doi: 10.1007/s10620-014-3486-7
15. Lampertico P, Soffredini R, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti A, Buti M, Esteban R, Zaltron S, Vavassori A, Castelli F, Viganò M, Rumi MG, Vinci M, Belli LS, Cologni G, Rizzi M, Milanese M, Strazzabosco M, Minola E, Giorgini AM, Zuin M, Salmi A, Colombo S, Fracassetti O, Del Poggio P, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Colombo AE, Bellati G, Angeli E, Gubertini GA, Rizzardini G, Fasano M, Santantonio T, Terreni NM, Spinzi G, Facchetti F, Invernizzi F, Mangia G, Colombo M. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Dig Liv Dis. 2014;46(suppl 1):e14. doi: 10.1016/j.dld.2014.01.033
16. Mamonova NA, Sukhareva GV, Chulanov VP, Karandashova IV, Lebedeva EB, Pimenov NN. Efficacy of entecavir in lamivudine-refractory patients with chronic hepatitis in early lamivudine-to-entecavir switching: preliminary analysis of the results of a three-year study. Infektsionnye Bolezni. 2014;12(1):81-6 (In Russ)
17. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, Tanwandee T. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res. 2017;47(3):E161-E168. doi: 10.1111/hepr.12743
18. Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003
19. Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17(1):39. doi: 10.1186/s12876-017-0596-7
20. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37-46. doi: 10.1111/jvh.12025
21. Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat. 2017;24(suppl 1):29-35. doi: 10.1111/jvh.12794
22. Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20(2):O90-O100. doi: 10.1111/1469-0691.12220
23. Efremova OS, Kozhevnikova GM, Voznesenskiy SL, Alikeeva GK. Effectiveness of modern nucleoside analogues in treatment of patients with HBeAg-negative chronic hepatitis В. Infektsionnye Bolezni. 2013;11(4):5-11 (In Russ.)
24. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014;28:153-9. doi: 10.1016/j.ijid.2014.09.004
25. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22(5):504-10. doi: 10.1111/jvh.12358
26. Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol. 2018;42(1):40-7. doi: 10.1016/j.clinre.2017.06.008
27. Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2009;5:789-98. doi: 10.2147/tcrm.s5318
28. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283-92. doi: 10.1002/hep.26885
29. Wang J, Du LY, Zhu X, Chen EQ, Tang H. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Ind J Med Microbiol. 2015;33(5):20-5. doi: 10.4103/0255-0857.148827
30. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(1):95. doi: 10.1016/j.cmi.2015.05.035
31. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1
32. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93. doi: 10.1002/hep.23785
33. Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol: WJG. 2015;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598
34. Chulanov VP. Resistance to antiviral drugs in chronic hepatitis В. Farmateka. 2010;(4):20-6 (In Russ.)
35. Abdurakhmanov DT, Moiseev SV. The safety of long-term tenofovir treatment in patients with chronic hepatitis B. Klinicheskaya Farmakologiya i Terapiya. 2014;23(2):20-5 (In Russ.)
36. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223-33. doi: 10.1038/ajg.2014.145
37. Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. Yonsei Med J. 2018;59(3):383-8. doi: 10.3349/ymj.2018.59.3.383
38. Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, Chotiyaputta W, Nimanong S. Efficacy and Safety of Entecavir Treatment of Chronic Hepatitis B Patients in Real-world clinical Practice: 968. Hepatology. 2013;58:672A. doi: 10.1002/hep.26856
39. Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gure S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials: 229. Hepatology. 2014;60:313A-314A. doi: 10.1002/hep.27486
Авторы
Э.К. Ибрагимов1, Д.Т. Абдурахманов1, Т.П. Розина1,2, Е.Н. Никулкина1, Е.Л. Танащук1, А.В. Одинцов1, С.В. Паневкина2, С.В. Моисеев1,2
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова», Москва, Россия
1 I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
2 M.V. Lomonosov Moscow State University, Moscow, Russia
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова», Москва, Россия
________________________________________________
1 I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
2 M.V. Lomonosov Moscow State University, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.